Also, CPX‐351 has showed encouraging outcomes when used with venetoclax, a BCL‐2 inhibitor, in both de novo AML and a subset of R/R AML patients who have undergone extensive pretreatment. The gene discussed is BCL2; the disease is acute myeloid leukemia.